AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01671787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate
Description: Subjects will receive 300mg of Tenofovir disoproxil fumarate (TDF) over 28 days of therapy
Study NCT00324415 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: 400 mg/m2 IV Day -7 (1 week before the cycle 1, Day 1 cisplatin/5-FU and RT), then 250 mg/m2 IV Days 1, 8, 15, 22, 29, 36 and 43 (a minimum of 6 and a maximum of 8 doses of cetuximab will be administered, including the loading dose)
Study NCT02147158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo tablet.
Study NCT00877643 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Upstream therapy
Description: Aldosterone receptor antagonists and statins, dietary restrictions, counseling, and cardiac rehabilitation.
Study NCT00877643 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional rhythm control
Description: Usual care for atrial fibrillation and heart failure according to the present guidelines
Study NCT01898468 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pericostal Closure Technique
Study NCT01898468 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intracostal Closure Technique
Study NCT02478411 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cycle ergometer physiotherapy
Description: 15 minutes of cyclo ergometer physiotherapy with MOTOmed ® Letto 2 device with passive, motor-assisted and active-resisted exercise of the lower and upper extremity, and 15 minutes of conventional physiotherapy
Study NCT02478411 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physiotherapy
Description: 30 minutes of conventional physiotherapy
Study NCT00857207 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal Management Training
Description: Enhanced Goal Management Training is a 10-week group therapy that teaches strategies to improve an individual's ability to complete everyday tasks.
Study NCT00324415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 75 mg/m2 IV on Day 1 (cycle 1) and Day 29 (cycle 2)
Study NCT00324415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: 1000 mg/m2/day by continuous intravenous infusion on Days 1-4 (cycle 1) and Days 29-32 (cycle 2)
Study NCT00324415 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Irradiation to tumor site and inguinal nodes beginning on cycle 1, Day 1 cisplatin/5-FU (minimum 45.0 Gy \[5 weeks if given on schedule and without interruption\], maximum 54.0 Gy \[6 weeks if given on schedule and without interruption). IMRT may be used at the discretion of the treating physician.
Study NCT03277183 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Low dose erythropoietin
Description: Subjects randomized to this arm will receive low-dose of EPO administered thrice weekly
Study NCT03277183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose erythropoietin
Description: Subjects randomized to this arm will receive the same cumulative dose of EPO administered as a high-dose of EPO every 2 weeks
Study NCT03713710 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pap testing
Description: Women will be approached in the community by a Peer Health Educator and scheduled an appointment for a Pap testing at the local health department
Study NCT03713710 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Choice
Description: Women will be approached in the community by a Peer Health Educator and they will be given a choice between scheduling an appointment for a Pap testing at the local health department or engage in self-sampling for HPV testing at home
Study NCT03435432 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glucose
Description: Glucose drink
Study NCT03435432 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: Control
Study NCT02244437 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Study NCT01417091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPS804
Study NCT04428697 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sungurtekin Technique
Description: Sungurtekin technique was performed through the base of the posterior fissure; thus, no additional incision was necessary in the lithotomy position. The mucosa was dissected along the submucosal plane, starting at the hypertrophic papilla, and extended for 1.5 cm, a 0.5-cm section of the bottom part of the internal anal sphincter was measured and marked with a ruler. Next, the internal sphincter bundle was measured with a sterile scale and a mark was placed at 1 cm towards the proximal end. The internal sphincter cut with cautery .
Study NCT04428697 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sungurtekin Technique
Description: Sungurtekin technique was performed through the base of the posterior fissure; thus, no additional incision was necessary in the lithotomy position. The mucosa was dissected along the submucosal plane, starting at the hypertrophic papilla, and extended for 1.5 cm, a 0.5-cm section of the bottom part of the internal anal sphincter was measured and marked with a ruler. Next, the internal sphincter bundle was measured with a sterile scale and a mark was placed at 1 cm towards the proximal end. The internal sphincter cut with cautery .
Study NCT04122703 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: percutaneous tibial nerve stimulation (PTNS)
Description: The PTNS treatments will be given in 30 min sessions. The PTNS treatment consists of inserting a 34-gauge needle electrode approximately 5 cm cephalad to the medial malleolus and, as well as placing a PTNS surface electrode on the ipsilateral calcaneus. To keep the electrode placement consistent with the sham treatment, 2 inactive transcutaneous electrical nerve stimulation (TENS) surface electrodes are also added, 1 placed under the little toe and 1 on the top of the foot. The PTNS lead set is connected to the Urgent PC stimulator, and a current level of 0.5 to 10 mA at 20 Hz is delivered until the flexion of the big toe is observed or the patient reports a radiating sensation at the sole of the foot.
Study NCT04122703 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham procedure
Description: The sham treatment, involves simulating the sensation of the PTNS needle insertion at the same location using a Steritberger placebo needle. This is a blunt tip needle which simulates the sensation of a needle prick when touched to the skin, however, the blunt tip retracts into the handle when pressed into the skin. This creates the illusion of the needle entering the skin, without breaking the skin's surface. An inactive PTNS surface electrode is also placed on the ipsilateral calcaneus. The two TENS surface electrodes, placed in the same location as the PTNS treatment, are active and deliver stimulation mimicking the sensory effects of the PTNS. However, since no electrode needles were inserted near the tibial nerve, there will be no tibial nerve stimulation
Study NCT00889876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin group
Description: 2000 mg/day for one year
Study NCT00889876 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 3 times/week with a personal coach for one year. Endurance training.
Study NCT00716014 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TD101
Description: TD101 is injection into a callus on the bottom of one of the patient's feet
Study NCT00716014 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline (placebo)
Description: A normal saline solution (placebo) is injected into one of the patient's feet.
Study NCT02502812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clop F1
Description: A single oral dose of clopidogrel (bisulfate) 75 mg tablet will be administered with approximately 240 mL water in fasted state.
Study NCT02244437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Study NCT03605706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: Subjects receive SHR-1210 intravenous at the dose 3mg/kg on Day 1 every 2 weeks
Study NCT03605706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX4
Description: Subjects receive FOLFOX4 treatment on D1-D2 of every 2 weeks
Study NCT03605706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects receive placebo of SHR-1210 intravenous at the dose 3mg/kg on Day 1 every 2 weeks
Study NCT02588183 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ArticFont Advance ST Cryoenergy Balloon Catheter
Description: PV isolation using the ArticFont Advance ST Cryoenergy Balloon Catheter
Study NCT02760550 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: Participants of all three groups completed a questionnaire.
Study NCT02629952 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blueberry Tea
Description: Blueberry Tea
Study NCT01073423 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Music Therapy
Description: 1-hour music therapy sessions, administered in group format 3 times per week for 8 weeks.
Study NCT01073423 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: 1-hour yoga sessions administered in group format 3 times per week for 8 weeks
Study NCT01429129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy
Description: Nicotine transdermal patches as per product monograph
Study NCT03861013 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multidimensional stress prevention program (GeDStress)
Description: The multidimensional stress prevention program (GeDStress) is composed of 8 session of 2-hour weekly sessions and integrated cognitive and behavioral strategies, mindfulness-based activities, emotional regulation and social skills exercises. Brief homework activities were given between sessions. The groups were composed by a maximum of 8 students and were led by two trained clinical psychologists.
Study NCT03204253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rFSH + r-LH in combination
Description: 29 women stimulated with rFSH supplemented by rLH in the late follicular phase started at the same time of starting the antagonist administration.
Study NCT03204253 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rFSH alone
Description: 32 women who were stimulated with recombinant FSH alone
Study NCT03532074 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: assessment of bowel symptoms before surgery
Description: validated questionnaires (Knowles-Eccersley-Scott-Symptom Questionnaire and Gastrointestinal Quality of Life Index) are filled in by patients with rectosigmoid endometriosis before surgery
Study NCT03532074 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: assessment of rectosigmoid during laparoscopy
Description: indocyanine green (0.25 mg/kg) is administered through peripheral line. A near-infrared camera-head (KARL STORZ Gesellschaft mit beschränkter Haftung \& Co., Tuttlingen, Germany) is used to visualize bowel perfusion before and after the removal of the rectosigmoid nodule. To estimate the vascularization, a scale with a score between 0 and 4 is used
Study NCT03532074 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: follow up and assessment of bowel symptoms after surgery
Description: validated questionnaires (Knowles-Eccersley-Scott-Symptom Questionnaire and Gastrointestinal Quality of Life Index) are filled in by patients with rectosigmoid endometriosis after surgery
Study NCT03532074 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: assessment of rectosigmoid perfusion during robot-assisted laparoscopy
Description: indocyanine green (0.25 mg/kg) is administered through peripheral line. The robotic Firefly imaging system (daVinciXi surgical platform; Intuitive Surgical, Sunnyvale, CA) is used to visualize bowel perfusion before and after the removal of the rectosigmoid nodule. To estimate the vascularization, a scale with a score between 0 and 4 is used
Study NCT05338723 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin 20mg
Description: 20 mg of oral rosuvastatin 24 hours prior to the first cycle of chemotherapy and once daily for the rest of the follow-up period (6 months).
Study NCT01263808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol 150 µg
Description: Once daily (QD) via single-dose dry powder inhaler (SDDPI)
Study NCT01263808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol 300 µg
Description: QD via SDDPI
Study NCT01263808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol 600 µg
Description: QD via SDDPI
Study NCT01263808 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: QD via SDDPI
Study NCT01263808 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo/moxifloxacin
Description: Placebo QD via SDDPI for 14 days, followed by a single dose of moxifloxacin 400 mg
Study NCT05049408 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MMP-1 Enzyme Linked Immunosorbent assay (ELISA)
Description: The MMP-1 ELISA is to measure salivary MMP-1 levels of participants
Study NCT03769129 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: microwave ablation
Description: microwave ablation
Study NCT05638399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg/ml [Prolia]
Description: 60 mg subcutaneously per 6 month
Study NCT05638399 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronate
Description: 5mg, intravenous infusion once a year
Study NCT01936480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400mg once time
Study NCT01936480 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Moxifloxacin 400mg once time
Study NCT01835392 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Preconditioning
Description: Lower limb ischemia/reperfusion cycles
Study NCT01835392 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Sham placement of blood pressure cuff without inflation
Study NCT01252823 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation of ILR
Description: Subcutaneous implantation of ILR under local anesthesia
Study NCT01332227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir
Description: Capsules, Oral, 300mg, Once daily, 48 weeks
Study NCT01332227 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Atazanavir
Description: Capsules, Oral, 300mg, Once daily, 48 weeks
Study NCT01332227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir (heat-stable)
Description: Tablets, Oral, 100 mg, Once daily, 48 weeks
Study NCT01332227 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ritonavir (heat-stable)
Description: Tablets, Oral, 100 mg, Once daily, 48 weeks
Study NCT01332227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: Tablets, Oral, 400 mg, Twice daily, 48 weeks
Study NCT01332227 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tenofovir/Emtricitabine
Description: Tablets, Oral, 300/200 mg, Once daily, 48 weeks
Study NCT01677273 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Hydrolyzed casein
Description: 30 g protein/supplement, 4 supplements/visit
Study NCT01677273 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Intact casein
Description: 30 g protein/supplement, 4 supplements/visit
Study NCT01677273 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Intact whey protein
Description: 30 g protein/supplement, 4 supplements/visit
Study NCT00981981 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Wheat bran
Description: 21g per day of ready to eat breakfast cereal containing wheat bran with 8g of total dietary fiber and 0.5g beta-glucan.
Study NCT00981981 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 3g high MW
Description: 20.2 grams per day of ready to eat cereal containing 6g total dietary fiber and 3g oat beta glucan with high molecular weight
Study NCT00981981 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 4g medium MW
Description: 28.5g ready to eat cereal containing 8g total dietary fiber and 4g oat beta glucan with medium molecular weight
Study NCT02988752 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electronic Mobile Device
Description: Measure C/D Ratio With An Equipment Attached To A Ophthalmoscope That Will Determine C/D Ratio Without Touching Patient's Eyes. To Perform It We Need Mydriatic Conditions.
Study NCT02988752 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Optical Coherence Tomography
Description: Measure C/D Ratio With OCT, Considered Gold Standard Equipment
Study NCT03769129 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: microwave ablation
Description: microwave ablation
Study NCT01896921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Switch to Maraviroc + Raltegravir or Dolutegravir
Description: Change HIV-infected patients on stable, suppressed ART regimens for at least 1 year to experimental regimen of Maraviroc + Raltegravir or Dolutegravir for 48 weeks
Study NCT05234645 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kefir consumption
Description: Following confirmation of eligibility and the provision of informed consent, recruited participants were provided with a 4-week supply of kefir (Live Kefir Company, Pontefract, UK) being instructed to consume 150ml of Kefir per day for the whole 4-week period. No break periods of kefir consumption were offered to any of the participants. In addition, they were instructed to not change their usual dietary habits and exercise routine for the study duration.
Study NCT03824522 — intervention group
Intervention type: BIOLOGICAL
Intervention: ADYNOVATE
Description: Pegylated recombinant human factor VIII
Study NCT01372787 — intervention group
Intervention type: PROCEDURE
Intervention: Assessment of Therapy Complications
Description: Ancillary studies
Study NCT01372787 — intervention group
Intervention type: OTHER
Intervention: Medical Chart Review
Description: Ancillary studies
Study NCT01372787 — intervention group
Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT01372787 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT01868009 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ELLIPTA
Description: Novel dry powder inhaler (placebo) with 30 doses (2 strips with 30 blisters per strip)
Study NCT01868009 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DISKUS
Description: Multidose dry powder inhaler (placebo) containing a foil strip worth 60 blisters (1 strip with 60 blisters per strip)
Study NCT02060461 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FS200 femtosecond laser LASIK
Study NCT02060461 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IntraLase femtosecond laser LASIK
Study NCT00981981 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 3g medium MW
Description: 21.1g of ready to eat cereal containing 6g total fiber and 3g oat beta glucan with a medium molecular weight
Study NCT00981981 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 4g low MW
Description: 28.7g ready to eat cereal containing 8g total dietary fiber and 4g oat beta glucan with low molecular weight
Study NCT02916173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Chorionic Gonadotrophin
Description: 250 unit intramuscular
Study NCT02155218 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Injection Rate
Description: Normally an IV is placed in an arm and the gadolinium contrast (30-40 cc, depending on patient size) is administered through the IV with a power injector as a single bolus. Subjects will have a test bolus and main bolus.
Study NCT02916173 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: human chorionic gonadotrophin + gonadotrophin releasing hormone agonist
Description: 250 unit intramuscular + 1 mg subcutaneous
Study NCT02943408 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: person-centered mental health intervention
Description: We anticipate that the PCMHI will be comprised of three, one-hour sessions offered over three to six weeks, scheduled at the participants' preference. Sessions will be one-on-one and the peer support specialist interventionist.
Study NCT02943408 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: health and wellness
Description: The control condition will be an educational health and wellness intervention for stress related disorders that will match the experimental condition for time and attention. The control condition will be three, one hour, individual sessions covering the symptom cycle, managing stress, and identifying social supports.
Study NCT02784483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab (1200mg via IV infusion)
Description: Patients will get atezolizumab every 21 days for up to 1 year